E.V. BOBYKIN, S.A. KOROTKIKH, R.V. BUSLAEV

Ural State Medical University, 3 Repin St., Ekaterinburg, Russian Federation, 620028

  Bobykin E.V. ― Cand. Med. Sc., Assistant Professor, Assistant Professor of the Ophthalmology Department, tel. (343) 214-80-00, e-mail: [email protected]

Korotkikh S.A. ― D. Med. Sc., Professor, Head of the Ophthalmology Department, tel. (343) 214-86-67, e-mail: [email protected]

Buslaev R.V. ― clinical resident of the Ophthalmology Department, tel. (343) 214-80-00, e-mail: [email protected]

The 12-month monitoring after «switching» from ranibizumab to aflibercept in the study group (n=21) revealed a statistically significant improvement in the anatomic parameters of the macula (a decrease in the central thickness of the retina from 325.3±20.2 to 263.2±17.1 μm {p<0,05} and the volume of the macula from 7.77±0.28 to 6.93±0.24 mm³ (p<0.05}), as well as a tendency to increase the best corrected visual acuity (from 0.39±0.05 to 0.43±0.05, p> 0.05). In 7 (33.3%) cases, the tactic of returning to the original drug («switch back») was applied for various reasons. The change in therapy as a single intravitreal injection performed during recurrences of the disease activity, did not contribute to a significant change in the number of injections (decrease from 3.19±0.22 to 2.81±0.34, p> 0.05) and adherence of patients to treatment (an increase in the proportion of patients with low compliance from 43.8 to 50.0% of patients; p>0.05) as compared with the 12 months preceding the study.

Key words: neovascular («wet») age-related macular degeneration, ranibizumab, aflibercept switching, switch back.

REFERENCES

1. Heier J.S., Brown D.M., Chong V., et al. VIEW 1 and VIEW 2 Study Groups Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology, 2012, vol. 119, no. 12, pp. 2537-2548. DOI: 10.1016/j.ophtha.2012.09.006.
2. Schmidt-Erfurth U., Kaiser P.K., Korobelnik J.-F., et al. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology, 2014, vol. 121, no. 1, pp. 193-20. DOI: 10.1016/j.ophtha.2013.08.011.
3. Kulikov A.N., Sosnovskiy S.V., Gribanov N.A. et al. Evaluation of the effectiveness of angiogenesis inhibitor replacement in tachyphylaxis of neovascular age-related macular degeneration to systematic antiangiogenic therapy. Vestnik Rossiyskoy voenno-meditsinskoy akademii, 2017, no. 2 (58), pp. 105-108 (in Russ.).
4. Budzinskaya M.V., Plyukhova A.A., Sorokin P.A. Resistance to anti-VEGF-therapy in exudative age-related macular degeneration, 2017, vol. 133, no. 4, pp. 103-108 (in Russ.). 10.17116/oftalma20171334103-108.
5. Jørstad Ø.K., Faber R.T., Moe M.C. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Acta Ophthalmol, 2017, vol. 95, no. 5, pp. 460-463. DOI: 10.1111/aos.13480.
6. Seguin-Greenstein S., Lightman S., Tomkins-Netzer O. A meta-analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age-related macular degeneration following switching to treatment with aflibercept. J. Ophthalmol, 2016, 2016:4095852, 8 pages. http://dx.doi.org/10.1155/2016/4095852.
7. Spooner K., Hong T., Wijeyakumar W., et al. Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis. Clinical Ophthalmology, 2017, no. 11, pp. 161-177.
8. Kulikov A.N., Sosnovskiy S.V., Gribanov N.A. et al. Short-term results of transition to aflibercept with tachyphylaxis for ranibizumab in patients with neovascular age-related macular degeneration. Sovremennye tekhnologii v oftal’mologii, 2017, no. 1, pp. 158-162 (in Russ.).
9. Bobykin E.V., Korotkikh S.A. The nearest results of the angiogenesis inhibitor change in the treatment of neovascular age-related macular degeneration in conditions of real clinical practice. Prakticheskaya meditsina, 2017, no. 3 (104), pp. 43-46 (in Russ.).
10. He L., Silva R.A., Moshfeghi D.M., et al. Aflibercept for the treatment of retinal pigment epithelial detachments. Retina, 2016, vol. 36, no. 3, pp. 492-498.
11. Despreaux R., Cohen S.Y., Semoun O. et al. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice. Graefes Arch. Clin. Exp. Ophthalmol, 2016, vol. 254, no. 4, pp. 639-644. DOI: 10.1007/s00417-015-3084-1.
12. Waibel S., Matthé E., Sandner D. Results of Re-switch from Intravitreal Aflibercept to Ranibizumab in Patients with Exudative Age-related Macular Degeneration. Klin. Monbl Augenheilkd, 2017, Jun 2. DOI: 10.1055/s-0043-106308 [Epub ahead of print] German.
13. Holz F.G., Tadayoni R., Beatty S., et al. Multi-Country Real-Life Experience of Anti-Vascular Endothelial Growth Factor Therapy for Wet Age-Related Macular Degeneration. Br. J. Ophthalmol, 2014, vol. 99, no. 2, pp. 220-226. DOI: 10.1136/bjophthalmol-2014-305327.
14. Korotkyh S., Bobykin E., Zhiborkin G., Morozova O. Compliance to Antiangiogenic Treatment in Russian Patients with Neovascular Age-Related Macular Degeneration. Ophthalmic Res, 2016, vol. 56 (suppl. 1), p. 1. DOI:10.1159/000446561.